SonoThera raised an oversubscribed $125 million in a Series B to advance ultrasound-mediated genetic medicines into clinical development. The financing was led by Vida Ventures and includes strategic and financial backers such as ARK Invest, Otsuka Pharmaceutical, UCB Ventures, and Leaps by Bayer. The company plans to progress lead programs in Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease, leveraging its RIPPLE ultrasound delivery approach and PORE payload engineering platform. SonoThera is positioning the platform to support redosing by addressing conventional gene therapy limitations tied to delivery and immune responses. SonoThera said it expects to initiate its first DMD clinical trial in 2027, underscoring that the money is being allocated to clinical readiness and expanding delivery capabilities across tissues.